Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-79 (Cancelled)

A method for improving reducing the size or improving Claim 80 (Currently Amended) the appearance of a closed wound comprising administering to the closed wound, orally administering, administering by injection or some combination thereof, a therapeutically effective amount of a composition comprising a suitable pharmaceutical carrier and at least one non-steroidal anti-inflammatory agent selected from the group consisting of: salicylic acid; aryl, substituted or unsubstituted aralkyl, allyl, and substituted or unsubstituted, linear, branched, or cyclic alkyl esters of salicylic acid; sulindac sulfide; sulindac sulfone; sulfasalazine; or pharmaceutically acceptable salts or combinations thereof; acetylsalicylic acid; aryl, substituted or unsubstituted aralkyl, allyl, and substituted or unsubstituted, linear, branched, or cyclic alkyl esters of acetylsalicylic acid; sodium salicylate; ibuprofen; celecoxib; rofecoxib; flufenamic acid; indomethacin; nabumetone; naproxen; or pharmaceutically acceptable salts or combinations thereof, wherein administering the composition improves at least one non-steroidal antiinflammatory agent reduces the size or improves the appearance of the closed wound and wherein the closed wound is selected from the group consisting of a wound caused by laceration; a wound caused by avulsion; a wound caused by burn; a wound caused by radiation; a wound caused by chemical facial peel; and a wound caused by accident.

Claim 81 (Cancelled)

Claims 82 (Previously Presented) The method of claim 80, wherein the closed wound is a normal scar, a hypertrophic scar, a keloid scar, a Dupuytren's contracture, a Peyronnie's Disease, a reactive scar, an excessive post-operative scar or a fibrotic scar.

Claims 83-86 (Cancelled)

Claim 87 (Previously Presented) The method of claim 80, wherein the at least one non-steroidal anti-inflammatory agent is administered in an amount from about 0.1 to about 10 percent by weight of the pharmaceutically acceptable carrier.

Claim 88 (Cancelled)

Claim 89 (Currently Amended) The method of claim 80, wherein the non-steroidal anti-inflammatory agent is present in a thermal insulating material, a gel, a hydrogel, or a sponge.

Claims 90-91 (Cancelled)

Claim 92 (Currently Amended) The method of claim 89, wherein the at least one non-steroidal anti-inflammatory agent is present in an amount of up to about 40 percent of the weight of the thermal insulating material, the gel, the hydrogel, or the sponge.

Claim 93 (Previously Presented) The method of claim 80, further comprising administering at least one agent selected from the group consisting of an anti-irritant, an anti-microbial agent, an anti-prurient agent, a deodorant agent and combinations thereof.

Claims 94 – 100 (Cancelled)

Claim 101 (Previously Presented) The method of claim 80, wherein the non-steroidal anti-inflammatory agent is present in an amount from about 40 micrograms to about 400 micrograms per square centimeter of the tissue comprising a closed wound.

Claim 102 (Previously Presented) The method of claim 101, further comprising oral administration of at least one agent selected from the group consisting of anti-irritant,

anti-microbial, anti-prurient agent, non-steroidal prostaglandin E2 inhibitor, deodorant agent, and combinations thereof.

Claim 103 (Currently Amended) A kit for improving reducing the size or improving the appearance of a closed wound, wherein the closed wound is selected from the group consisting of a wound caused by laceration; a wound caused by avulsion; a wound caused by burn; a wound caused by radiation; a wound caused by chemical facial peel; and a wound caused by accident, comprising:

a hydrogel;

at least one non-steroidal anti-inflammatory agent selected from the group consisting of: salicylic acid; aryl, substituted or unsubstituted aralkyl, allyl, and substituted or unsubstituted, linear, branched, or cyclic alkyl esters of salicylic acid; sulindac sulfide; sulindac sulfone; sulfasalazine; or pharmaceutically acceptable salts or combinations thereof; acetylsalicylic acid; aryl, substituted or unsubstituted aralkyl, allyl, and substituted or unsubstituted, linear, branched, or cyclic alkyl esters of acetylsalicylic acid; sodium salicylate; ibuprofen; celecoxib; rofecoxib; flufenamic acid; indomethacin; nabumetone; naproxen; or pharmaceutically acceptable salts or combinations thereof, wherein the at least one non-steroidal anti-inflammatory agent is effective for improving reducing the size or improving the appearance of a closed wound; and

a suitable pharmaceutical carrier.

Claims 104-106 (Cancelled)

Claim 107 (Previously Presented) The kit of claim 103, further comprising a sterile solution for mixing two or more members selected from the group consisting of the hydrogel; the at least one non-steroidal anti-inflammatory agent; and a suitable pharmaceutical carrier.

Claim 108 (Previously Presented) The kit of claim 103, further comprising at least one agent selected from the group consisting of a metallic anti-microbial agent, an anti-

prurient agent, a non-steroidal prostaglandin E2 inhibitor, a deodorant agent, and combinations thereof.

Please add the following new claims:

Claim 109 (new) The method of claim 89, wherein the thermal insulating material is selected from the group consisting of a gel, a hydrogel, and a sponge.

Claim 110 (new) The method of claim 92, wherein the thermal insulating material is selected from the group consisting of a gel, a hydrogel, and a sponge.